Related Experiment Videos
Antitumour imidazotetrazines and gene expression
1CRC Experimental Chemotherapy Group, Aston University, Birmingham, England.
Acta Oncologica (Stockholm, Sweden)
|January 1, 1988
Summary
Imidazotetrazinones like Temozolomide decrease DNA methylation. Modified DNA inhibits DNA methylase, suggesting a mechanism for altered gene expression in cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Imidazotetrazinones are a class of drugs investigated for their effects on DNA methylation.
- Temozolomide (TMZ), a 3-methyl analogue, reduces 5-methylcytosine levels in DNA.
- Drug sensitivity and resistance influence the hypomethylation effects of these agents.
Purpose of the Study:
- To investigate the mechanism by which imidazotetrazinones cause DNA hypomethylation.
- To compare the effects of Temozolomide and its 3-ethyl analogue, CCRG 82019, on DNA methylation and methylase activity.
Main Methods:
- In vitro alkylation of calf thymus DNA with Temozolomide and CCRG 82019.
- Assay of DNA methylase activity using S-adenosyl-L-methionine and M. lysodeikticus DNA.
- Analysis of DNA-protein complex stability.
Main Results:
- Alkylated DNA, but not free drug or unmodified DNA, inhibited eukaryotic DNA methylase activity.
- DNA modified with CCRG 82019 was a more potent inhibitor of DNA methylase than DNA modified with Temozolomide.
- CCRG 82019-modified DNA formed more stable complexes with nuclear proteins compared to Temozolomide-modified DNA.
Conclusions:
- DNA hypomethylation by imidazotetrazinones may occur via inhibition of DNA methylase by drug-modified DNA.
- The differential effects of modified DNA on methylase activity and protein binding could explain varying drug potencies.
- Alterations in 5-methylcytosine levels in DNA are potentially crucial for modulating gene expression by these anticancer agents.